{"links":{"html":"https://www.erudio.com/reports/dial-nct05255302","json":"https://www.erudio.com/reports/dial-nct05255302.json","markdown":"https://www.erudio.com/reports/dial-nct05255302.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"dial-05255302"}},"request":"https://www.erudio.com/contact?report=dial-05255302"},"offer":{"cited_commentary_sources":15,"verified_hcp_statements":29,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":11,"optional":true,"price_per_verified_person_usd":15,"price_usd":165,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"dial-nct05255302"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=dial-05255302","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/dial-nct05255302","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-28T22:39:03.915947Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":1},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Phase II: 18-month overall survival (OS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Phase III: overall survival"},{"claim_count":5,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":4,"title":"Secondary endpoints"},{"claim_count":5,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":9,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":7,"title":"The comparison"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":4,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":2,"coverage":"discussed","id":"A1","source_count":2,"title":"Patient selection, response and biomarker-guided duration"},{"claim_count":5,"coverage":"discussed","id":"A2","source_count":3,"title":"Finite treatment, late recurrence and the two-year threshold"},{"claim_count":5,"coverage":"discussed","id":"A3","source_count":3,"title":"Academic de-escalation rationale and DICIPLE precedent"},{"claim_count":2,"coverage":"discussed","id":"A4","source_count":2,"title":"Practical treatment-intensity framing alongside PERSEE"}],"counts":{"cited_sources":16,"claims_by_expression_type":{"comparison":5,"interpretation":10,"opinion":6,"primary_context":1,"question":3,"restatement":2,"uncertainty":1,"unspecified":1},"claims_by_kind":{"attributed_opinion":19,"interpretation":2,"protocol_statement":1,"source_observation":7},"clinician_statements":9,"evidence_units":26,"findings":6,"organisational_accounts":5,"people_cited":12,"people_identity_verified":11,"people_total":12,"screened_sources":95,"verified_claims":29},"depth":"thin","findings_index":[{"id":"F1","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":1,"views":4},"has_counterview":false,"limitations":2,"links":{"context":0,"support":7},"ma_question":true,"named_voices":3,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"Encouraging phase II findings are explicitly distinguished from established safety or non-inferiority"},{"id":"F2","structure":{"claims":10,"claims_by_group":{"comparisons":3,"experience":0,"questions":1,"restated":1,"views":5},"has_counterview":true,"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":4,"passages":5,"sources":5,"sources_by_kind":{"commentary":5}},"title":"The favorable reading combines similar reported survival with less toxicity"},{"id":"F3","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":3},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Patient selection and biomarker-guided duration remain open questions"},{"id":"F4","structure":{"claims":3,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":1,"views":1},"has_counterview":false,"limitations":3,"links":{"context":0,"support":3},"ma_question":true,"named_voices":1,"passages":3,"sources":3,"sources_by_kind":{"commentary":2,"registry":1}},"title":"Practical enthusiasm includes a consequential mischaracterization of the duration question"},{"id":"F5","structure":{"claims":6,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":1,"views":3},"has_counterview":false,"limitations":3,"links":{"context":1,"support":6},"ma_question":true,"named_voices":5,"passages":5,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Finite-course arguments support the question, but do not resolve the six-month threshold"},{"id":"F6","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":4},"has_counterview":false,"limitations":3,"links":{"context":1,"support":5},"ma_question":true,"named_voices":3,"passages":4,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Academic de-escalation is valued, with DICIPLE treated as precedent rather than a DIAL outcome"}],"medical_affairs_question":"What evidence and patient-selection criteria would justify stopping pembrolizumab at six months without treating early survival similarity as proven equivalence?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Encouragement is not a validated six-month stopping rule"},{"id":"section-2","level":2,"title":"Why similar survival and lower toxicity attract favorable reactions"},{"id":"section-3","level":2,"title":"Who might stop, and could biomarkers help?"},{"id":"section-4","level":2,"title":"Keep the practical questions separate"},{"id":"section-5","level":2,"title":"Finite treatment is a rationale, not proof of the six-month threshold"},{"id":"section-6","level":2,"title":"Academic de-escalation and the limits of precedent"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":3}],"id":"T1","label":"Primary endpoint: Phase II: 18-month overall survival (OS)"},{"findings":[],"id":"T2","label":"Primary endpoint: Phase III: overall survival"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":5}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":5}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":5}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-28T22:39:03.915947Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-28T23:06:40Z","record_hash":"a13606aeaeee6477cf9d93f8571d857b470617c72035202466904f3a9a214f39","release_hash":"4c1d9d2673b25e9566998f57ea6ae3f06a1ccb46d3f9067bdaa15124085e9f81","report_id":"erudio-nct05255302","run_id":"d9a92956-478d-4a1b-bb65-a4218fc866c4","schema_version":"5.0","slug":"dial-05255302","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"DIAL asks whether to stop or continue pembrolizumab after six months of first-line chemoimmunotherapy in controlled metastatic NSCLC. Clinicians in the sources reviewed express enthusiasm for shorter treatment, while acceptance of a stopping strategy remains conditional. The prospect of less toxicity is welcomed; survival evidence draws scrutiny. Patient selection and biomarker-guided duration remain open questions. The sources reviewed for this edition place DIAL's main results at ESMO 2026.","meta_description":"95 sources screened · 29 verified statements (9 from clinicians verified by NPI or staff page) from 16 sources · 6 findings. Updated Oct 28, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-3cac19dcef912b84c229"],"id":"F1","paraphrase":"An X post asks what level of certainty DIAL provides for the treatment-duration decision.","publication_caveats":{"reason":"Publication-specific caveats are not stated for this source.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-10-25","title":"Encouraging phase II findings are explicitly distinguished from established safety or non-inferiority"},{"cited_claim_ids":["claim-1c0982cf01832207c746"],"id":"F3","paraphrase":"An X post raises DIAL's question of whether immunotherapy can be stopped safely after six months.","publication_caveats":{"reason":"Publication-specific caveats are not stated for this source.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-10-21","title":"Patient selection and biomarker-guided duration remain open questions"}]},"publication":{"approved_at":"2026-10-28T23:06:40Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":95},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 matching source (1 podcast) could not be read and is not included.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","32 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The report represents only the sources reviewed for this edition. Reposts, organizational or account-level posts, and reports of talks do not establish a count of independent HCP endorsements or a consensus.","Searches emphasized trial identifiers and names; unnamed references, short acronyms and transcription variants may be missing, including discussion of the same clinical question without the DIAL name.","One podcast was unavailable, additional checking of a video transcript was unsuccessful, and four potentially relevant social-media passages were not fully assessed. Additional views or qualifications may therefore be absent.","No DIAL results publication was available among the reviewed sources, and no separate protocol was listed in the registry material. Numerical phase II findings are presented as authors' reports rather than conclusions from a reviewed trial results publication.","The cited safety summaries use different adverse-event categories and values. Their denominators, grades and statistical uncertainty are not available in the statements cited, so the figures should not be pooled or treated as interchangeable.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Comments span posts dated 2023–2026 and different events. Post dates are not session dates and do not demonstrate changes in an author's position."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":15,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":15,"methods":1},"count":16,"evidence_window":{"end":"2026-10-25","start":"2023-06-04"},"retrieval_snapshot":"2026-10-28T21:38:54.253057Z","timeline":[{"count":1,"week":"2023-W22"},{"count":1,"week":"2023-W23"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2024-W06"},{"count":1,"week":"2024-W40"},{"count":1,"week":"2025-W13"},{"count":9,"week":"2026-W43"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05255302:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05255302:context","quote_policy":"short_quote_link_out"},{"id":"openfda:caef07ce-066b-4c48-98dc-974b05ebbbe0:20260618","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7xhpnihaskebihwzpuwn22pp-3lgewhqm7xc2a","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-bcen47iol6hccqoufvtk7wt6-3lkpxqo2fwc24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-edgecie3ey6jibr5ax6jv7up-3mise6cuksc24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-gbd4dskldh6jyfquke6vm2ag-3mbmqkqu3o22d","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-u6u7n3swplvmomxc2pcijf5o-3mukjkax5cc23","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:457752","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6459b2","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:f8ecdf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1148314671054819329:7afbf4ec-5bd0-4f2f-881f-b918eca831e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1173176785695121408:fad8bb08-4b12-4ae1-912e-f5e3e0492b25","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1257826175717568513:0e8423b5-e79b-4a02-8350-51804c53608b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1258780197752410113:28bd647f-08af-4199-a4b6-491beac3505b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1273766257314103297:5b25dbe0-ab08-470e-a190-135155631a64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1320774270352457728:9506faa4-6859-499f-8c78-7ce868b6fcf2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1330679763715940355:d67b3a2f-0511-43d0-9cd9-a47d0e28aabd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1474065013094637577:7e7dc174-75a8-46d6-b103-b9f58cae0fa5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1496822018565554179:04983050-3f0b-4bd7-b5eb-8241c2f45085","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1585682523564146693:18585721-c6a2-4de7-a7ce-5e5a41d968a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1589267523656364032:dca8390d-3578-4390-8b87-4b26d52e2778","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1589674961169698817:756dbbd1-1bb6-4556-9230-9142b453d1af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1633098139770003461:3c969c97-bc05-4114-95f4-1f3a0d7ccf48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1634139964618276866:0904b1af-6ba6-41dd-b716-497b7e215175","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1639633170877546506:7f17503b-713f-4dee-9132-9cc9e0b2244a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1657944265174003714:403420fb-c514-4b29-8491-f5fbf1183bdd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665411578668146689:9fc8e196-c0d6-4cfd-a8b7-1d8dc0de5552","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665607789148876800:12031f11-7f8b-462c-99a4-6938072d65e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1672917527653937152:bb16edf8-59fc-446d-8480-42f12f5d4bb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1682934628930420743:fb7a3b2c-7d9c-4f4b-9ebb-a551771a9a4d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701412737618976809:7dbaf495-5fdb-404c-b000-d153bcc32f36","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715647096777281678:d820b6d2-0f0e-4bca-a169-a26b07dcf5f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1736401362533970213:4b3ffc32-5f5d-40b7-ad32-99c5f96bf130","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1747738554376302598:3c0e9462-58b8-4760-b864-66d19b10a4fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1755844017827254387:d52f56e5-21e9-4cc7-a836-3fcfcace33b0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1762215199501615337:9855b74f-3187-4987-80d5-3e08bdf9a434","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1842195556007133617:04cb2a35-5eea-40f1-9ef7-313c4df8ac90","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1842613453439090789:b9f7a059-b14a-4d84-ab71-df7f9b138f28","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1905613517119512839:10e7548b-a804-40d8-bad5-d58b233735c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1905663158246650230:b9f3c750-84f8-42b1-9aba-c296a44ea81a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1935981312906518755:835cbb70-1cdd-4d36-bc7e-13705c620d13","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1937549592830033968:828324da-cd51-4f8e-8c22-0f097d943a9e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1955058454415991108:12cc2c1c-e9ba-46a0-8b1f-23f41c06badb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1955603801483940011:ef16a4fa-2506-4e5b-b32e-9726293691d4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1965865387050033496:2056501f-2d14-4696-a725-0dfa8849eb2a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1969692061759570219:ba76528c-a820-4869-9a2b-1cd89d2e66f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1976163020507132183:9d3180f2-c637-4194-b101-50b774e14256","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1983840690447823322:cd4a8137-a8fc-400f-a0e2-bcb2d87119cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1990438529206296863:f518771e-af9e-4dc0-bd01-38f0258a8b2d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2016210323099856991:3389a901-b649-43ad-97f4-c5f8c866e325","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2016952045010387030:b2e4074a-364a-4faf-9beb-cd3694cbc8a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018817882105495825:cb98a0c9-8874-4cb0-b009-5c844988cc12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2043825130258792540:79c3b344-9b96-4ae6-b058-d97cd5f25268","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2048413173871505585:310fdf66-02aa-400b-a353-868f9ae393ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050877677574262871:dc45541f-e3cd-4239-8fbe-3ec7d48e0b45","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055650337051034083:617a982c-f5ff-4dcc-8a21-83779f721cb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058470133538992302:f1430ab9-e01a-49fc-837a-66d7b7904542","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2073460653776384065:57bcc803-5ccc-43d7-833e-e4fabbea66ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074604687773388838:aa048634-47cb-4aac-aac0-7337f1d86609","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2076706025340837996:8b91b451-0e70-471c-b7d7-ebe1955f895c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2078629438024044569:f85d08c4-b9f0-49e5-9742-46b27b5bbc2d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2083994776521633901:3c59efd0-eb7d-43e1-992b-32ccc695369c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099102292808995035:9477fd43-9271-4f08-bc21-00758971b9c4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103516126252527833:9488addf-584f-4cac-8079-ea229bb93af1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103831957339873739:dbc1133c-498e-4882-8504-51a8fb985653","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112449695201034605:bc66ddc1-2b56-4493-8f1b-1ecf4457140b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112846605963407601:e98c7409-89d3-4dda-90bd-9e9348cefece","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112899204347765199:750a4823-5807-431a-8ab8-de94124827ae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112900334104273094:f5d7c278-64fe-40da-a4cc-70ead8e282fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112911160416633189:db4ea10c-75d2-4ee8-aca1-b807937f8d81","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112947042960240711:1f1b404b-0fe9-4e0a-803d-c58aad91b0f1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113276244506624163:c0bdcd40-0aa2-4424-843f-447e7098607c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113561393152540999:e27bd256-e61e-4763-849e-50910935d1ec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113819441083682817:105bc1af-f0af-4b67-8f46-290b87dc2f7c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114027566524936510:5d0c4d03-4d4c-4bac-82b4-47277654c6ba","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114272736210280556:d5bf7b2c-cc7d-4b8b-9b9b-549568c362ab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114272889390174699:99635fa9-942a-4039-b65f-2f91a86cc9e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114273125995041087:47e816d8-8ed7-4f07-a461-50dea592bb58","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114273987219910796:cdee220e-d72b-43fb-ae39-478cb1413c1d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114278033616183421:febda7af-1c83-403f-a97d-b4ebef86471b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114288021235511594:75586817-2013-4006-94ab-3d4dedc4414f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114292608939786733:807fad82-60fc-477d-b58e-e7fcf522930e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114294995859427624:422d9f10-068d-453e-b499-bb24d837b112","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114298418226983153:804e2452-865f-4f11-bbc8-f2c4f584c932","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114313430660210699:71e31067-7060-46ab-b550-c224ffeb6050","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114695298442559919:af0ceb3a-b292-4e28-ab84-f9ea0647f4f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114761749056360512:6b5993bc-afd3-4c1c-9325-aa97dd0c5f57","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114764232155865123:357ca5b8-157b-4ea7-9e10-84c7020858f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:695988287589060609:a7c38580-1fae-4854-8182-12ae664964ce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:935498379790094336:eff68021-66bd-4b1b-bf21-d6edb5595aea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:1941406946973843500","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:0xacn3k0zEY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:5rx8_8DB_D8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:KEsouB0Uv98","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:bmx7oHWxH8o","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:sflJ-Z4zDJA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:xXR5xBBfhZA","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":5,"linkedin_post":0,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":80,"x_video":1,"youtube":6},"by_evidence_role":{"commentary":95},"count":95,"evidence_window":{"end":"2026-10-26","start":"2016-02-06"},"retrieval_snapshot":"2026-10-28T22:06:38.403191Z","timeline":[{"count":1,"week":"2016-W05"},{"count":1,"week":"2017-W48"},{"count":1,"week":"2019-W28"},{"count":1,"week":"2019-W37"},{"count":2,"week":"2020-W19"},{"count":1,"week":"2020-W25"},{"count":1,"week":"2020-W44"},{"count":1,"week":"2020-W48"},{"count":1,"week":"2021-W51"},{"count":1,"week":"2022-W08"},{"count":1,"week":"2022-W43"},{"count":1,"week":"2022-W44"},{"count":1,"week":"2022-W45"},{"count":1,"week":"2023-W03"},{"count":2,"week":"2023-W10"},{"count":1,"week":"2023-W12"},{"count":1,"week":"2023-W20"},{"count":1,"week":"2023-W21"},{"count":1,"week":"2023-W22"},{"count":1,"week":"2023-W23"},{"count":1,"week":"2023-W25"},{"count":1,"week":"2023-W28"},{"count":1,"week":"2023-W29"},{"count":1,"week":"2023-W37"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2023-W47"},{"count":1,"week":"2023-W50"},{"count":1,"week":"2023-W51"},{"count":1,"week":"2024-W03"},{"count":1,"week":"2024-W06"},{"count":1,"week":"2024-W09"},{"count":1,"week":"2024-W13"},{"count":1,"week":"2024-W25"},{"count":1,"week":"2024-W30"},{"count":2,"week":"2024-W40"},{"count":1,"week":"2024-W48"},{"count":1,"week":"2025-W04"},{"count":1,"week":"2025-W12"},{"count":2,"week":"2025-W13"},{"count":1,"week":"2025-W25"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2025-W27"},{"count":2,"week":"2025-W33"},{"count":1,"week":"2025-W37"},{"count":1,"week":"2025-W38"},{"count":1,"week":"2025-W41"},{"count":1,"week":"2025-W44"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2026-W01"},{"count":2,"week":"2026-W05"},{"count":1,"week":"2026-W06"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W16"},{"count":2,"week":"2026-W17"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W28"},{"count":2,"week":"2026-W29"},{"count":1,"week":"2026-W31"},{"count":1,"week":"2026-W36"},{"count":1,"week":"2026-W37"},{"count":2,"week":"2026-W39"},{"count":1,"week":"2026-W42"},{"count":20,"week":"2026-W43"},{"count":3,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: pembrolizumab before randomization","status":"unmapped"},{"reason":"Unmapped registry intervention: chemotherapy","status":"unmapped"},{"brand_names":["Alimta"],"label":"pemetrexed","slug":"pemetrexed"},{"reason":"Unmapped registry intervention: pembrolizumab after randomization","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Metastatic NSCLC","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"DIAL","aliases":["DIAL","De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction","A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (± Pemetrexed) Until Progression Versus Observation (± Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy Plus Pembrolizumab Induction Treatment in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)"],"brief_title":"De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Metastatic NSCLC"],"enrollment":{"count":1360,"type":"ESTIMATED"},"interventions":[{"name":"Pembrolizumab before randomization","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Chemotherapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pemetrexed","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pembrolizumab after randomization","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05255302","official_title":"A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (± Pemetrexed) Until Progression Versus Observation (± Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy Plus Pembrolizumab Induction Treatment in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)","overall_status":"RECRUITING","phase":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2025-05","type":"ESTIMATED"},"primary_endpoints":[{"description":"Rate of patients not dead 18 months after inclusion","measure":"Phase II: 18-month overall survival (OS)","timeFrame":"18 months after inclusion"},{"description":"Time from date of inclusion to the date of death due to any cause","measure":"Phase III: overall survival","timeFrame":"about 24 months after randomization"}],"registry_last_updated":"2025-04-01","registry_url":"https://clinicaltrials.gov/study/NCT05255302","short_name":"DIAL","short_name_basis":"registry_acronym","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","start_date":{"date":"2022-05-02","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2, phase3","study_ids":[{"id":"IFCT-2103","type":"sponsor_study_id"},{"id":"2021-006044-27","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}